$Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)$

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)

BackgroundLow-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). In confirmatory trials, proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab substantially lowered LDL-C and reduced cardiovascular morbidity and mortality....

Full description

Bibliographic Details
Main Authors:	Isabella Sudano, Francois Mach, Tiziano Moccetti, Thilo Burkard, Christian Fahe, Alain Delabays, Hans Rickli, Pierre-Frédéric Keller, Jörn Dopheide, Sereina Bodenmann, Tom Fiolka, Georg Ehret, David Spirk
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	atherosclerotic cardiovascular disease heterozygous familial hypercholesterolemia LDL-C target attainment PCSK9 inhibition statin intolerance
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2022.953040/full

Similar Items

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
by: Chang-Wook Nam, et al.
Published: (2019-11-01)

Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
by: Angela Dardano, et al.
Published: (2021-07-01)

Homozygous familial hypercholesterolemia
by: Ravi Kumar Parihar, et al.
Published: (2012-01-01)

Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries
by: Marcello Arca, et al.
Published: (2023-11-01)

Current causes of death in familial hypercholesterolemia
by: Victoria Marco-Benedí, et al.
Published: (2022-08-01)

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale
by: Tamio Teramoto, et al.
Published: (2017-06-01)

New Trends and Therapies for Familial Hypercholesterolemia
by: Fahad Alnouri, et al.
Published: (2022-11-01)

Nuclear Receptor PXR in Drug-Induced Hypercholesterolemia
by: Mikko Karpale, et al.
Published: (2022-01-01)

Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report
by: Massimiliano Allevi, et al.
Published: (2023-06-01)

Mortality Benefit of Alirocumab: A Bayesian Perspective
by: Christopher Labos, et al.
Published: (2019-10-01)

Competing Genetic Traits and Their Influence on LDL Cholesterol Concentration in Familial Hypercholesterolemia
by: Christopher Song, MD, et al.
Published: (2024-01-01)

Retargeting the management of hypercholesterolemia – focus on evolocumab
by: Colletti A, et al.
Published: (2016-09-01)

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
by: Harold E. Bays, et al.
Published: (2017-08-01)

The panorama of familial hypercholesterolemia in Latin America: a systematic review[S]
by: Roopa Mehta, et al.
Published: (2016-12-01)

PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2021-03-01)

Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study
by: Kasper Aalbæk Kjærgaard, et al.
Published: (2022-07-01)

Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins
by: Victoria Marco-Benedí, et al.
Published: (2021-08-01)

Variable and Severe Phenotypic Expression of the “Lebanese Allele” in Two Sisters with Familial Hypercholesterolemia
by: Chahine J, et al.
Published: (2021-07-01)

Editorial: Genetics of Familial Hypercholesterolemia: New Insight
by: Alpo Vuorio, et al.
Published: (2021-05-01)

Metabolomic Approach to Screening Homozygotes in Chinese Patients with Severe Familial Hypercholesterolemia
by: Zhiyong Du, et al.
Published: (2023-01-01)

Long‐Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening
by: Kasper Aalbæk Kjærgaard, et al.
Published: (2017-11-01)

Myocardial strain impairment, heterozygous familial hypercholesterolemia and systemic arterial hypertension: Is there a link?
by: Antonio Vitarelli
Published: (2021-06-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)

Effect of alirocumab on cataracts in patients with acute coronary syndromes
by: Gaspard Suc, et al.
Published: (2023-06-01)

Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients
by: Anthony Matta, et al.
Published: (2023-07-01)

Burden of cardiovascular disease in a large contemporary cohort of patients with heterozygous familial hypercholesterolemia
by: Jean Ferrières, et al.
Published: (2022-12-01)

Editorial: Genetics of familial hypercholesterolemia: New insight—Volume II
by: Alpo Vuorio, et al.
Published: (2022-10-01)

The Digenic Causality in Familial Hypercholesterolemia: Revising the Genotype–Phenotype Correlations of the Disease
by: Amina Kamar, et al.
Published: (2021-01-01)

An Untargeted Lipidomic Analysis Reveals Depletion of Several Phospholipid Classes in Patients with Familial Hypercholesterolemia on Treatment with Evolocumab
by: Andrea Anesi, et al.
Published: (2021-12-01)

Efficacy and safety of the use of alirocumab in real clinical practice
by: Viktoria A. Korneva, et al.
Published: (2023-01-01)

Genetic and Clinical Characteristics of Patients With Homozygous and Compound Heterozygous Familial Hypercholesterolemia From Three Different Populations: Case Series
by: Tatiana Marusic, et al.
Published: (2020-09-01)

The Importance of Arterial Stiffness Assessment in Patients with Familial Hypercholesterolemia
by: Beáta Kovács, et al.
Published: (2022-05-01)

Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
by: Nagham N. Hindi, et al.
Published: (2021-08-01)

A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
by: Rana K, et al.
Published: (2019-09-01)

Allicin and Capsaicin Ameliorated Hypercholesterolemia by Upregulating LDLR and Downregulating PCSK9 Expression in HepG2 Cells
by: Nantiya Nawaka, et al.
Published: (2022-11-01)

Prevalence and Impact of Apolipoprotein E7 on LDL Cholesterol Among Patients With Familial Hypercholesterolemia
by: Hayato Tada, et al.
Published: (2021-04-01)

Case report: Unusual coexistence between familial hypercholesterolemia and familial hypobetalipoproteinemia
by: Kei Sasaki, et al.
Published: (2022-08-01)

Economic expertise of alirocumab in standard lipid lowering therapy insusceptibility
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

First Line CombinAtion Therapy in the Treatment of Stage II and III Hypertension (FLASH)
by: David Spirk, et al.
Published: (2020-03-01)

Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
by: Dipti Athavale, et al.
Published: (2018-10-01)